144 related articles for article (PubMed ID: 22946545)
1. Abatacept for systemic lupus erythematosus: the outlook.
Mok CC
Expert Opin Biol Ther; 2012 Dec; 12(12):1559-61. PubMed ID: 22946545
[TBL] [Abstract][Full Text] [Related]
2. Abatacept in the treatment of lupus.
Hoi AY; Littlejohn GO
Expert Opin Biol Ther; 2012 Oct; 12(10):1399-406. PubMed ID: 22870890
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.
Merrill JT; Burgos-Vargas R; Westhovens R; Chalmers A; D'Cruz D; Wallace DJ; Bae SC; Sigal L; Becker JC; Kelly S; Raghupathi K; Li T; Peng Y; Kinaszczuk M; Nash P
Arthritis Rheum; 2010 Oct; 62(10):3077-87. PubMed ID: 20533545
[TBL] [Abstract][Full Text] [Related]
4. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
Hachulla É
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
[TBL] [Abstract][Full Text] [Related]
5. Is there still a role for abatacept in the treatment of lupus?
Hoi A; Littlejohn G
Expert Opin Biol Ther; 2014 Sep; 14(9):1345-50. PubMed ID: 25005704
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.
Haggerty HG; Abbott MA; Reilly TP; DeVona DA; Gleason CR; Tay L; Dodge R; Aranda R
J Rheumatol; 2007 Dec; 34(12):2365-73. PubMed ID: 18050376
[TBL] [Abstract][Full Text] [Related]
7. Challenges and opportunities in SLE clinical trials.
van Vollenhoven RF
Curr Opin Rheumatol; 2013 Sep; 25(5):606-15. PubMed ID: 23917158
[TBL] [Abstract][Full Text] [Related]
8. Abatacept for the treatment of systemic lupus erythematosus.
Pimentel-Quiroz VR; Ugarte-Gil MF; Alarcón GS
Expert Opin Investig Drugs; 2016; 25(4):493-9. PubMed ID: 26878310
[TBL] [Abstract][Full Text] [Related]
9. [The management of systemic lupus erythematosus with biological therapies].
Malaise O; von Frenckell C; André B; Malaise MG
Rev Med Suisse; 2013 Aug; 9(395):1507-11. PubMed ID: 24024419
[TBL] [Abstract][Full Text] [Related]
10. Biologics in SLE: towards new approaches.
van Vollenhoven RF; Parodis I; Levitsky A
Best Pract Res Clin Rheumatol; 2013 Jun; 27(3):341-9. PubMed ID: 24238691
[TBL] [Abstract][Full Text] [Related]
11. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
12. Block and tackle: CTLA4Ig takes on lupus.
Davidson A; Diamond B; Wofsy D; Daikh D
Lupus; 2005; 14(3):197-203. PubMed ID: 15807196
[TBL] [Abstract][Full Text] [Related]
13. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
Wofsy D; Hillson JL; Diamond B
Arthritis Rheum; 2012 Nov; 64(11):3660-5. PubMed ID: 22806274
[TBL] [Abstract][Full Text] [Related]
14. When biologics should be used in systemic lupus erythematosus?
Gottenberg JE; Lorenzo N; Sordet C; Theulin A; Chatelus E; Sibilia J
Presse Med; 2014 Jun; 43(6 Pt 2):e181-5. PubMed ID: 24933678
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
16. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy for systemic lupus erythematosus.
Dall'Era M; Wofsy D
Discov Med; 2010 Jan; 9(44):20-3. PubMed ID: 20102681
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Furie R; Nicholls K; Cheng TT; Houssiau F; Burgos-Vargas R; Chen SL; Hillson JL; Meadows-Shropshire S; Kinaszczuk M; Merrill JT
Arthritis Rheumatol; 2014 Feb; 66(2):379-89. PubMed ID: 24504810
[TBL] [Abstract][Full Text] [Related]
19. Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges.
Schröder JO; Zeuner RA
Curr Drug Discov Technol; 2009 Dec; 6(4):252-5. PubMed ID: 20025592
[TBL] [Abstract][Full Text] [Related]
20. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH; Durez P; Hallegua D; Aranda R; Becker JC; Nuamah I; Vratsanos G; Zhou Y; Moreland LW
J Rheumatol; 2006 Nov; 33(11):2162-6. PubMed ID: 17014006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
